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Abstract 
 Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a 
cornerstone in treatment of patients with cardiovascular diseases especially in those with heart 
failure (HF) due to their proven effect on surrogate and hard end-points. RAASi are also the 
basis in treatment of arterial hypertension and they are furthermore indicated to reduce 
events and target organ damage in patients with diabetes and chronic kidney disease, where 
they have specific indication because of the evidence of benefit. RAASi therapy, however, is 
associated with an increased risk of hyperkalaemia. Patients with chronic kidney disease and 
HF are at increased risk of hyperkalaemia and ~50% of these patients experience two or more 
yearly recurrences. A substantial proportion of patients receiving RAASi therapy have their 
therapy down-titrated or more often discontinued even after a single episode of elevated 
potassium (K+) level. 
Since RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease 
steps should, when hyperkalaemia develops, be considered to lower K+ level and enable 
patients to continue their RAASi therapy. The use of such measures are especially important in 
those patients with the most to gain from RAASi therapy. 
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Potassium (K+) is the most abundant cation in the body (50-75 mEql/kg body weight). Under 
physiological conditions, approximately 98% of total body K+ is located in the intracellular space 
and only 2% in the extracellular space. Hyperkalaemia defined as serum or plasma K+ > 5 
mmol/L (for K+ 1 mmol/L = 1 mEq/L) is a common electrolyte disorder that may develop due to 
increased K+ intake, reduced K+ excretion and shift of K+ from intracellular to extracellular 
space.  
Food is the primary source of K+ intake with the relative amounts of K+ differing greatly 
between foods. The highest amounts of K+ are found in fruits, vegetables and meat. However, a 
sometimes overlooked dietary K+ source comes from salt substitutes (i.e. Na+ chloride 
substituted by K+ chloride) and nutritional supplements. High K+ intake may cause 
hyperkalaemia if renal K+ excretion is impaired.  
The kidneys are, under normal conditions, responsible for up to 90-95% of K+ elimination with 
the colon being responsible for the majority of the remaining K+ excretion. However, the 
colonic excretion of K+ increases when renal function worsens. In fact, in patients with end-
stage renal disease faecal K+ secretion is 3-fold greater as compared to patients with normal 
renal function. This finding suggests that the colon might assume an accessory K+ excretory role 
and a modest compensatory mechanism for reduced renal K+ excretion.  While long-term 
regulation of K+ levels occurs mainly in kidneys, short-term regulation mainly occurs in skeletal 
muscles.  
Several common clinical conditions and drugs (Table 1) are known to cause or aggravate 
hyperkalaemia. Amongst these drugs, Renin angiotensin aldosterone system 
inhibitors/antagonists/blockers (RAASi) are those most frequently associated with 
hyperkalaemia in patients with cardiovascular disease, but against this must be counter-
balanced with the fact that they are among the drugs that confer the most significant survival 
benefit in patients with cardiovascular disease [1-8] .   
Guidance on how best to direct the management of cardiovascular patients in the sub-acute 
(post-emergency) and chronic phases of hyperkalaemia is in increasing demand due to the 
increasing use of RAASi. This document is an expert consensus on the optimum management of 
hyperkalaemia in the post-emergency phase in patients with cardiovascular disease, especially 
in those receiving or having a compelling indication to receive RAASi. 
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Hyperkalaemia 
K+ levels were traditionally measured in serum from coagulated blood but are now more often 
measured in plasma from heparinised blood. Serum levels may be up to ½ mEq/L higher than 
plasma levels. This is especially the case for high values. In addition, errors associated with 
blood sampling may also cause erroneously high K+ levels. These factors must be taken into 
consideration by the clinician, and must be clarified in any scientific study on hyperkalaemia. In 
the present document, we mostly use the expression K+ level since it is unclear in many studies, 
what was actually measured. 
The severity of hyperkalaemia can be classified as mild (>5.0 to <5.5 mEq/L) to moderate (5.5 
to 6.0 mEq/L) and to severe at thresholds (>6.0 mEq/L) (Figure 1). The risk for the development 
of arrhythmic emergencies and sudden arrhythmic death in patients with hyperkalaemia is 
widely variable as life-threating arrhythmias may occur at different thresholds and vary 
between different patients. Often K+ levels up to 6 mEq/L are found in patients without any 
signs of arrhythmia, especially if they have chronic kidney disease, diabetes or heart failure. In 
these patients, hyperkalaemia is often incidentally discovered whilst performing routine blood 
tests. Besides, the definition based on K+ levels, hyperkalaemia can be classified as acute or 
chronic or recurrent according to the onset and the number of hyperkalaemia episodes 
experienced. Chronic or recurrent hyperkalaemia is defined as K+ levels >5 mEq/L repetitively 
measured over a one-year period. Pseudo-hyperkalaemia refers to high K+ level in the test tube 
without hyperkalaemia in the body. This may be caused by release of K from blood or tissue 
during sampling. If pseudo-hyperkalaemia is suspected measurement should be repeated with 
blood sampled appropriately or eventually taken as an arterial sample. In case of haemolysis, 
the clinician should consider whether it occurs in the test tube or in the body [6-10].  
The occurrence of hyperkalaemia differs between in- and outpatients. It is present in 2-4% of 
the general population, and in 10-55% of patients hospitalized for any cause depending on the 
K+ level used to define hyperkalaemia in the different studies. Both the prevalence of 
hyperkalaemia and risk of recurrence increase as severity and number of comorbidities 
increase [11-28].  The incidence of hyperkalaemia increases with the severity of renal 
impairment, it is often iatrogenic, caused by concurrent drugs and nutritional/herbal 
supplements (Table 1).  In clinical practice, hyperkalaemia occurs in up to 73% of patients with 
advanced chronic kidney disease and in up to 40% of patients with chronic heart failure. It 
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leads to more frequent hospitalisations and increased mortality, especially when stringent 
monitoring is not performed [3,5,11-35]. 
Hyperkalaemia frequently occurs in patients with cardiovascular diseases (e.g. heart failure, 
arterial hypertension, coronary artery disease), in particular when combined with renal 
function impairment, diabetes and advanced age. Hyperkalaemia may be responsible for 
cardiac arrhythmias leading to cardiac arrest and death, with a resulting mortality rate of up to 
30%. Severe hyperkalaemia is an independent predictor of all-cause and in-hospital mortality 
and hospitalizations.  
Life-threatening hyperkalaemia requires immediate treatment with a combination of calcium 
carbonate and hyperosmolar sodium (if the individual has hyponatraemia) to stabilise the 
myocardial cell membrane; insulin w/wo glucose and/or beta adrenoceptor agonists (e.g. 
salbutamol) (off-label use in some EU Countries) and sodium bicarbonate to transfer K+ into the 
cells [17,22,30,36]. However, insulin salbutamol, and bicarbonate do not increase K+ excretion 
and only provide temporary benefit (1-4 hours). Thus, rebound hyperkalaemia can occur after 2 
hours. This suggests that treatment with a K+ lowering agent should be initiated as early as 
possible. Loop diuretics and potassium binders [mainly sodium polystyrene sulfonate (SPS), 
calcium polystyrene sulfonate (CPS) or patiromer sorbitex calcium (PSC) (Veltassa®) or sodium 
zirconium cyclosilicate (SZC) or (ZS-9)] can be used to promote the excretion via renal or 
gastrointestinal route, respectively. K+ increasing medicine should be stopped and K+ intake via 
food, drinks etc. should be reduced to a minimum. If these measures are ineffective, 
haemodialysis may be needed (Table 2).  
Despite being recommended for use, RAASi drugs are unfortunately seldom re-instated 
following an episode of hyperkalaemia at or after discharge even if a different clear 
precipitating cause of hyperkalaemia was detected and eliminated. The most common clinical 
scenario is that doses of RAASi are reduced, or they are simply discontinued; this is particularly 
true for MRAs. Although RAASi dose reduction or discontinuation may reduce the risk of 
reoccurrence of hyperkalaemia, discontinuation of RAASi is associated with an increased risk of 
worsening of the underlying cardiovascular condition and mortality [13,14,37-39]. 
 
RAASi and hyperkalaemia 
RAASi are the cornerstone of the treatment of patients with cardiovascular diseases (heart 
failure with reduced ejection fraction (HFrEF), arterial hypertension, coronary artery disease, 
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myocardial infarction (MI), left ventricular (LV) hypertrophy), with a class IA recommendation 
in current clinical guidelines due to the proven reduction of mortality and morbidity in HFrEF 
[16,20,40]. RAASi are the basis of the treatment of arterial hypertension, and in hypertensive 
patients an MRA must be implemented before resistant hypertension is diagnosed [15]. RAASi 
are also indicated to reduce events and target organ damage in patients with diabetes and 
chronic kidney disease where they have a specific indication because of the overwhelming 
evidence of benefit [15,17].  
Since RAASi increase K+ levels, RAASi-induced hyperkalaemia often limits the use of these drugs 
thereby offsetting their survival benefits. In hypertensive patients without risk factors 
for hyperkalaemia, the incidence of hyperkalaemia with RAASi monotherapy is 2% and 
increases to 5% with dual RAAS inhibition and to 5%-10% when dual therapy is administered 
in patients with heart failure or chronic kidney disease [14,31]. According to current guidelines 
MRAs should be implemented in therapy after an ACEi (or an ARB in intolerant patients) has 
been already initiated [15-17]. In patients with chronic HFrEF, in NYHA functional class II, and 
meeting specific inclusion and exclusion criteria, including an eGFR >30 ml/min/1.73 m2 and K+ 
level <5.0 mmol/L, eplerenone was both efficacious and safe when carefully monitored, even in 
subgroups at high risk of developing hyperkalaemia or worsening renal function [13]. 
Furthermore, in the RALES trial, the benefit of spironolactone was maintained in the setting of 
moderate hyperkalaemia, and clinical outcomes with spironolactone were superior to placebo 
when K+ levels remained <6.0 mEq/L [41]. In this trial, 13.5% and 40% of participants exhibited 
hyperkalaemia when treated with 25 and 50 mg daily of spironolactone. This finding suggests 
that limiting the maximum dose to 25 mg daily may reduce the risk of hyperkalaemia and 
argues against automatic discontinuation of MRAs when K+ levels rise >5.0 mmol/L.  Indeed, 
the clinical benefit of spironolactone and eplerenone remained even in those who developed 
modest elevations in K+ level in the RALES and EMPHASIS-HF trials [14,38,39]. Up to one third 
of New York Heart Association (NYHA) class II-IV heart failure patients starting an MRA 
develop hyperkalaemia (>5.0 mEq/L) over two years [14,42,43].  
Patients with cardiovascular disease and chronic kidney disease are at risk of hyperkalaemia 
and ~50% of these patients have two or more recurrences within 1 year [42-45]. Incidence 
rates of hyperkalaemia have been shown to be higher in HFrEF patients on MRA in the real 
world setting than in clinical trials (6-12%), i.e. when they are administered to higher-risk and 
unselected populations which did not receive K+ level and/or creatinine monitoring [44-47]. In 
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the real world setting the incidence of hyperkalaemia can be as high as 50% in unselected 
population of patients receiving RAASi [32, 34]. Despite this evidence and guideline 
recommendations, K+ levels are frequently under-monitored in patients treated with RAASi 
[35,48]. Therefore, quality improvement programs are needed to improve rates of laboratory 
monitoring for patients initiated on MRA therapy, particularly in high-risk patients.  
 
Hyperkalaemia and discontinuation of RAASi 
Hyperkalaemia or borderline high K+ levels are, together with symptomatic hypotension and 
worsening renal function, the main reasons that result in discontinuation, dose reduction or 
even non-initiation of RAASi therapy in patients with renal and cardiovascular diseases 
offsetting the survival benefits conferred by these drugs.  
A substantial proportion of heart failure (HF) patients are facing a RAASi dose adjustment even 
after a single instance of elevated serum K+ levels. According to the European Society of 
Cardiology Heart Failure Long-Term Registry recruiting 12,440 patients with HFrEF, RAASi were 
used in 92.2% and 67.0% of patients, respectively [48]. Less than one-third of patients were on 
guideline-recommended target doses (29.3% for ACEi, 24.1% for ARB and 30.5% for MRA). In 
about a third of the patients not achieving the target dosages, a clear reason was not reported 
(28.8% for ACEi, 29.3% for ARB, and 46.9% for MRA). Hyperkalaemia was the reason for non-
use of ACEi/ARB and MRA in 8.5% and 35.1% of patients, respectively [48].  
Among patients with chronic kidney disease RAASi were prescribed at the target guideline 
recommended dose in 19% to 26% of patients, at submaximal dose in 58% to 65% of patients 
and were discontinued during follow-up in 14% to 16% of patients [49]. Cardio-renal adverse 
events/mortality and mortality occurred in 34.3% and 11.0% of patients who discontinued 
RAASi inhibitors, 24.9% and 8.2% of patients on submaximal doses, and 24.9% and 4.1% of 
patients on maximum doses, respectively [49].  
Recently, the BIOSTAT-CHF reported that only 22% of patients with HFrEF achieved the 
recommended treatment dose for ACEi /ARB [50]. Reaching <50% of the recommended dose of 
ACEi/ARB doses was associated with an increased risk of death and/or heart failure 
hospitalization compared with patients reaching ≥100% [50].   
The importance of guideline adherence on prognosis has been recently highlighted by the 
QUALIFY global survey in 7,092 patients with HFrEF [51].  In this registry good adherence to 
guidelines was associated with a significant prognostic benefit, the adherence score was good 
Downloaded from https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvy015/4992013
by St George's University of London user
on 10 May 2018
 9 
in 67%, moderate in 25%, and poor in 8% of patients and the proportion of patients at target 
dose and at ≥50% of target dose was 27.9% and 63.3% for ACEi and 6.9% and 39.5% for ARBs, 
respectively [51]. 
Data from registries usually provide a more accurate picture than clinical trials on ‘real life’ 
situations. However, even registries can identify populations that are receiving better care 
compared to the general population.  Indeed, a recent comparison of patients enrolled and 
those not enrolled in the Swedish Heart Failure Registry showed that survival was substantially 
higher in the registry setting, and this was most likely due to better use of RAASi drugs in 
registry included patients [52]. 
 
Current guidelines and management of hyperkalaemia 
Current clinical guidelines recommend that patients with chronic hyperkalaemia should be 
started on a low K+ diet and have to be initiated on a non-K+ sparing diuretic or if already on a 
diuretic, to increase the dose [53-55]. All guidelines also suggest to eliminate K+ supplements 
and to discontinue drugs that compromise renal function such as NSAIDs and those that may 
increase K+ levels such as RAASi therapy, especially MRAs (Table 3). 
The ESC Heart Failure Guidelines suggest that if a short-term cessation of K+-retaining agents 
and RAASi is deemed necessary, this should be minimized and RAAS inhibitors should be 
carefully reintroduced as soon as possible while monitoring K+ levels [20].  
As recommended by several regulatory agencies, the chronic use of SPS alone or in conjunction 
with sorbitol should be avoided because its prolonged use may be associated with severe 
gastrointestinal side effects such as bowel necrosis [56]. SPS has never undergone rigorous 
testing in placebo-controlled clinical trials to prove its efficacy and safety for treatment of 
acute or chronic hyperkalaemia [57,59]. In addition, because Na+ is the counter exchange ion in 
SPS, caution is advised if it is administered to patients who do not tolerate even a small 
increase in Na+ load (i.e., those with heart failure, severe hypertension, or marked oedema) 
[59]. Here K+ binders with a different counter exchange ion (i.e. PSC) may be alternatives. 
 
Consensus on the implementation of RAASi therapies in patients with episodes of 
hyperkalaemia 
Since RAASi therapy reduces mortality and morbidity in patients with cardiovascular disease 
but can increase K+ levels, therapies aimed at lowering K+ levels and enabling patients to 
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continue RAASi therapy should be considered. Such an approach is already implemented in 
other fields of medicine, e.g in cancer where symptomatic therapy is used to enable use of 
cancer directed therapy (antiemetics and cytostatic drugs). The use of such an approach in 
patients with cardiovascular disease, who develop hyperkalaemia or borderline high K+ level 
under RAASi therapy may be of benefit to many including those who benefit most from RAASi 
therapy.  
 Thus, the recent availability of two new effective and safe K+ binders, PSC (Veltassa®) approved 
for clinical use in Europe and the USA, and sodium zirconium cyclosilicate (SZC) or (ZS-9),  
approved by European Medicines Agency (EMA) and under final stages of review (at the 
moment of writing of this manuscript) by United States Food and Drug Administration (US- 
FDA), are both developed to increase faecal K+ excretion mainly in the colon, and open new 
opportunities for the treatment of hyperkalaemia [60,61]. In clinical trials, both compounds 
have been shown to be effective to normalize elevated K+ levels, maintain normo-kalaemia 
over time and prevent the recurrences of hyperkalaemia in patients with hyperkalaemia on 
RAASi therapy [62,68].  
Therefore, for most patients with cardiovascular disease and chronic or recurrent 
hyperkalaemia, RAASi therapy should be optimised whenever possible and treatment with PSC 
or SZC (when approved) may be initiated. In the absence of clinical guidelines and of ad hoc 
randomised clinical trials with hard end points this consensus is based on inferred available 
evidence but will need to be confirmed by appropriate clinical trials [69-70] .  
In patients with hyperkalaemia an evaluation should be made of the patient´s diet, use of 
supplements, salt substitutes and nutraceuticals that contain K+ as well as of concomitant 
medications that may contribute to hyperkalaemia. Co-administration of drugs known to 
promote hyperkalaemia or reduce kidney function are not absolute contraindications but 
should prompt more frequent monitoring of K+ levels.  Kidney function must be determined 
and monitored.  A low-K+ diet and loop or thiazide diuretics that increase K+ excretion to 
reduce the occurrence of hyperkalaemia may be considered. Whenever K+ lowering therapy is 
initiated K+ levels should be closely monitored not only to follow the K+ lowering effect, but 
also to protect against development of hypokalaemia, which may be even more dangerous 
than hyperkalaemia.  
In general, RAASi therapy should be started at a low dosage starting an ACEi (ARB when 
indicated) first and an MRA thereafter and titrated to the maximum tolerated evidence-based 
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doses shown to reduce the risk of cardiovascular and renal events in clinical trials.  
In patients with K+ levels between 4.5 and 5 mEq/L not on maximum tolerated, guideline-
recommended target dose of RAASi therapy, it is recommended to titrate/start RAASi therapy 
and closely monitor K+ levels. If K+ levels raise above 5.0 mEq/L, K+ lowering measures should be 
initiated. 
In patients with as K+ levels >5 on maximum tolerated, guideline-recommended dose of RAASi 
therapy, treatment with a K+ lowering agent may be initiated as soon as K+ levels >5 mEq/L. K+ 
level should be monitored according to the clinical status and K+ lowering treatment should be 
maintained unless another aetiology for hyperkalaemia is identified. 
Finally, in patients with K+ levels >5 mEq/L not on maximum tolerated, guideline-recommended 
target dose of RAASi, therapy with K+ lowering agents should also be initiated and when K+ 
levels are <5 mEq/L titration of RAASi therapy should be implemented. Thereafter, K+ levels and 
renal function should be closely monitored and drug dose adjusted (Figure 2). 
 
Conclusion 
This consensus document is based on the available evidence and on expert opinion on the 
beneficial effect of RAASi therapies in patients with cardiovascular disease.  The use of the new 
K+ lowering agents may be of help in optimising RAASi therapies in patients with hyperkalaemia 
or at increased risk of developing it. However, the benefit of K+ lowering agents enabling and 
optimizing RAASi therapies on long term outcomes should be further evaluated in randomised 
clinical trials. 
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Table 1 
 
 
 
Drugs/substances that may cause hyperkalaemia 
 
1. Decreased potassium excretion: 
a. Potassium-sparing diuretics (eg, spironolactone, triamterene, 
amiloride) 
b. Beta-blockers 
c. NSAIDs 
d.  Sacubitril/valsartan 
e. Renin-angiotensin-aldosterone inhibitors (RAASi): ACE inhibitors, 
Angiotensin-receptor blockers, mineralocorticoid receptor antagonists 
f. Direct Renin inhibitors (Aliskiren) 
g. Mannitol 
h.  Cyclosporine or tacrolimus 
i. Pentamidine 
j. Trimethoprim-sulfamethoxazole 
k. Heparin 
l. Digitalis  
m. Calcineurin inhibitors 
n. Penicillin G 
2. Increased potassium intake/administration 
a. Potassium Supplements 
b. Salt Substitute (e.g. DASH) 
c. Fruits (Bananas, melons, orange juice) 
d. Alfalfa 
e. Amino Acids (Aminocaproic acid, Arginine, Lysine) 
f. Dandelion 
g. Dried toad skin 
h. Hawthorne Berry 
i. Horsetail 
j. Liliy of the Valley 
k. Milkweed 
l. Nettle 
m. Noni Juice 
n. Siberian Ginseng 
o. Stored blood products 
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Table 2 
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Table 3 
 
 
Existing recommendations on RAASi use according to K
+
 levels  
 
K
+
 levels Recommendation 
>6 Stop RAASi (ESC HF [20], NICE [7]) 
>5.5 mEq/L Reduce dose of/stop ACEI/ARB (K/DOQI [55-57]) 
5.1-5.5 K/DOQI (e): take measures to lower K
+
 when initiating RAASI 
>5  Do not start RAASis if >5.0 (K/DOQI [55-57], HFSA HF [63], NICE [7]) 
 Reduce dose of/stop RAASi if >5-0 (ACCF/AHA HF [18], ESC HF [20], K/DOQI 
[55-57]) 
 MRA not recommended if >5.0 (HFSA HF [63])  
 Maintain MRA between 4.0-5.0 (ACA/AHA [18]) 
 Do not routinely offer a RAASi to people with CKD if their pre-treatment K
+
 
levels are > 5.0 mEq/L 
A K
+
 lowering agent should be started. 
4.5-5 In patients not on maximal guideline-recommended target dose of RAASI 
therapy, it is recommended to up-titrate/start RAASi therapy and closely monitor 
K
+
 levels. 
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Figure 1  
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Figure 2 
 
 
  
 
 
 
Patients Recommendation 
Chronic or recurrent hyperkalaemia 
on RAASi therapy 
An approved K
+
-lowering agent may be initiated as soon as K
+
 
levels are confirmed as >5.0 mEq/L. Closely monitor K
+
 levels. 
Maintain treatment unless alternative treatable aetiology is 
identified 
Chronic or recurrent hyperkalaemia 
not on maximal tolerated 
guideline-recommended target 
dose of RAASi 
RAASi should be optimised and an approved K
+
-lowering agent 
may be initiated as soon as confirmed K
+
 levels are >5.0 
mEq/L. Closely monitor K
+
 levels. Maintain treatment unless 
alternative treatable aetiology is identified 
K+ levels of 4.5–5.0 mEq/L not on 
maximal tolerated, guideline-
recommended target  dose of 
RAASi therapy 
Initiate/up-titrate RAASi therapy and closely monitor K
+
 levels. 
If K
+  
levels rise above 5.0 mEq/L, initiate an approved  K
+
-
lowering agent 
K+ levels of >5.0–<6.5 mEq/L not 
on maximal tolerated, guideline-
recommended target dose of RAASi 
therapy 
Initiate an approved  K
+
-lowering agent. If levels <5.0 mEq/L 
are detected, up-titrate RAASi - K+ level should be closely 
monitored and K+ lowering treatment should be maintained 
unless another aetiology for hyperkalaemia is identified  
K+ levels of >5.0–<6.5 mEq/L on 
maximal tolerated, guideline-
recommended target dose of RAASi 
therapy 
Treatment with a K
+ 
lowering agent may be initiated. K
+ 
level 
should be closely monitored and K+ lowering treatment 
should be maintained unless alternative treatable aetiology 
for hyperkalaemia is identified  
K+ levels of >6.5 mEq/L on either 
maximal sub-maximal tolerated, 
guideline-recommended target 
dose of RAASi therapy 
Discontinue/reduce RAASi. Treatment with a K
+ 
lowering agent 
may be initiated as soon as K
+ 
levels >5.0 mEq/l. K
+ 
level 
should be closely monitored 
   
Flow diagram on the management of hyperkalaemia 
in patients with indication for RAASi 
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Legends 
 
Table 1 
Drugs/substances that may cause hyperkalaemia. 
NSAIDs=non-steroidal anti-inflammatory drugs 
DASH= Dietary Approach to Stop Hypertension 
 
 
Table 2 
Treatment of acute or chronic hyperkalaemia. 
Na= sodium, K=potassium, IV= intra-venous, PO= per os, PR= per rectum 
 
Table 3 
Existing recommendations on RAASi use according to serum K+ levels 
RAASi= Renin angiotensin aldosterone system inhibitor 
K=potassium 
MRA= mineralocorticoid receptor antagonists 
 
Figure 1 
Definitions of normo-kalaemia, hyperkalaemia and hypokalaemia.   
Hyperkalaemia can be classified as mild, moderate or severe.  Thresholds for the definition 
of the severity of hyperkalaemia differ between different classifications. This may mainly 
be due to different methods used to determine K+ levels 
 
 
Figure 2 
Flow diagram on the management of hyperkalaemia in patients with indication for RAASi therapy. 
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